EIDX - Eidos Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.85
-1.48 (-4.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close36.33
Open35.88
Bid34.84 x 900
Ask34.90 x 900
Day's Range34.57 - 36.57
52 Week Range8.89 - 41.35
Volume113,790
Avg. Volume167,239
Market Cap1.283B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.25
Trade prices are not sourced from all markets
  • 3 Stocks Corporate Insiders are Buying Now
    TipRanks6 days ago

    3 Stocks Corporate Insiders are Buying Now

    For investors, following insiders can be a viable trading strategy. Corporate officers, board members, and investment funds are indeed careful about the way they allocate funds, so following their purchase activity can lead to great investment tips. More importantly, these are the entities with a more direct knowledge of the companies and business sectors. And they put that knowledge to use when planning stock purchases.TipRanks offers the Insiders’ Hot Stocks, a data tool that tracks over 43,000 corporate insiders and reveals their latest moves. We’ve used it to find three affordably priced stocks that are showing positive insider signals. Looking for the stocks, we used the Major Event Strategy, the most successful of four filters available on TipRanks for sorting insider trades.Insider Trading Strategies Sinclair Broadcast Group, Inc. (SBGI)Sinclair is the largest TV operator in the US, reaching 40% of American households with 193 stations in 100 local markets. The network is focused mainly in the Midwest and South. TV, with its advertising reach, is a lucrative business and Sinclair generated revenues over $3 billion in FY2018.Executive Chairman David D. Smith, son of the company’s founder, made the most recent insider purchase of SBGI stock, buying $21.7 million worth on July 10. The purchase increased his holding in the company by 395,000 shares, making him one of the largest shareholders in Sinclair.This insider purchase came just one day before five-star analyst Daniel Kurnos, of Benchmark, affirmed his buy rating and $90 price target on the stock. Smith’s purchase, and Kurnos’s review, come after the company publicized Q2 revenue guidance of $721 million – in line with previous estimates, and one month before the August 8 Q2 earnings release. In his note to investors, Kurnos says, “Sinclair completed the RSN-Charter (CHTR) negotiations, that Dish (DISH) remains the biggest "wildcard" for the RSNs, but he is optimistic Sinclair will prevail.” His price target, with its 52% upside for the stock, reflects his optimism.Overall, Sinclair has a strong buy analyst consensus rating, with a unanimous 5 buys over the past three months. Shares are selling for $59, and the $69 average price target indicates an 18% upside potential.>>Click Here to see the full list of Analyst Ratings Eidos Therapeutics, Inc. (EIDX)Biotech offers great opportunity it any company able to find a solid niche. Eidos Therapeutics focuses on developing new treatments for the two forms of transthyretin (TTR) amyloidosis (ATTR) disease. While the two disease forms – cardiomyopathy and polyneuropathy – manifest differently, they share the same cause. Eidos is working on a drug, AG10, designed to stabilize the malformed protein (TTR) that causes ATTR disease.Research of this type requires a great deal of capital, and that can be raised through stock sales. Recently, on July 8, Eidos received a capital infusion greater than $100 million, when four major stock owners increased their holdings. BridgeBio Pharma, the parent company of Eidos, along with three top company officers – Neil Kumar, CEO, and Ali Satvat and Eric Aguiar, both on the Board of Directors – all purchased $26.3 million worth of EIDX common shares. The transactions brought the total corporate insider purchases of EIDX in the last three months to $218.35 million – a clear vote of confidence by company officers in Eidos’ research pipeline and future prospects.Their optimism is borne out by a recent analyst review. Yasmeen Rahimi, of Roth Capital, believes “Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial.” She also notes “an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80%.” In line with the upbeat prospects for the drug, she boosted her price target on EIDX by 45%, from $28 to $51. Her new price target suggests an upside potential of 27% for the stock.In the last three months, Eidos as received 2 buy ratings, giving it a moderate buy from the analyst consensus. The average price target of $44.50 suggests an 11% upside from the current share price of $39.97.>>Click Here to see the full list of Analyst Ratings Beacon Roofing Supply, Inc. (BECN)Economic experts predict that the US housing market, which has shown a slowing trend since 2017, will continue to weaken into 2020. Slowing population growth, combined with lower incomes and higher debt levels among the millennial age cohort, are putting downward pressure on housing starts.But there is always some demand for new housing, and construction companies like Beacon Roofing, North America’s largest supplier of roofing products to the residential and commercial construction sectors, will always have customers. This optimistic outlook is borne out by Cd&R Investment Associates IX recent purchase, back on June 28, of $158 million worth of BECN stock. A purchase of this size, by an investment group, is a clear signal of confidence in the stock.A look at the analyst reviews will help to explain the confidence. SunTrust’s Keith Hughes said, on March 26, “that while adverse weather factors reduced expectations, the outlook for the rest of the year suggests minimal impact in future quarters. [R]oofing can actually see benefits from weather factors over the medium term as replacement demand rises.” Hughes set a price target of $44, suggesting an upside of 18%.Weighing in just last month, Raymond James analyst Sam Darkatsh concurred on the buy rating, and gave BECN a $40 price target.BECN’s analyst consensus rating is a moderate buy, with 1 buy and 2 hold ratings given in the last 90 days. Shares are selling for $37.20, so the average price target of $40 indicates a possible 7.5% upside.>>Click Here to see the full list of Analyst RatingsVisit TipRanks’ Insiders’ Hot Stocks, and find your own best investment.

  • Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount?
    Simply Wall St.20 days ago

    Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount?

    Does the July share price for Eidos Therapeutics, Inc. (NASDAQ:EIDX) reflect what it's really worth? Today, we will...

  • Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%?
    Simply Wall St.20 days ago

    Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%?

    Does the July share price for Eidos Therapeutics, Inc. (NASDAQ:EIDX) reflect what it's really worth? Today, we will...

  • GlobeNewswirelast month

    Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference

    Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25th at 2:40 p.m. EDT in New York, NY. AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in subjects with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated 90% average TTR stabilization at day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner.

  • GuruFocus.com2 months ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Eidos Therapeutics, Intrexon, AGNC Investment, Rattler Midstream and Discovery

  • Gene Therapy Parent BridgeBio Set to Go Public
    GuruFocus.com2 months ago

    Gene Therapy Parent BridgeBio Set to Go Public

    Conglomerate has 15 drug development programs at companies under its wing

  • 3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million
    American City Business Journals2 months ago

    3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million

    From rare diseases to cancer and NASH, this trio of companies would be the seventh, eighth and nine Bay Area life sciences IPOs this year.

  • Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the market. Hedge […]

  • Can Pfizer Leap Over the Competition With This Potential Blockbuster?
    Motley Fool2 months ago

    Can Pfizer Leap Over the Competition With This Potential Blockbuster?

    It's been nearly seven years since the FDA refused to approve tafamidis's first new drug application, and the field is a lot more crowded now.

  • GlobeNewswire2 months ago

    Eidos Therapeutics Reports First Quarter 2019 Financial Results

    SAN FRANCISCO, May 07, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2019 and provided an.

  • GlobeNewswire3 months ago

    Eidos Therapeutics to Present at Two Upcoming Investor Conferences

    SAN FRANCISCO, April 19, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences. Class of.

  • GlobeNewswire3 months ago

    Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results

    SAN FRANCISCO, April 15, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31,.

  • RM LAW Announces an Investigation of Eidos Therapeutics, Inc.
    PR Newswire4 months ago

    RM LAW Announces an Investigation of Eidos Therapeutics, Inc.

    BERWYN, Pa. , April 5, 2019 /PRNewswire/ --  RM LAW, P.C.  announces an investigation on behalf of Eidos Therapeutics, Inc. (NASDAQ: EIDX) ("Eidos Therapeutics" or the "Company") investors ...

  • Business Wire4 months ago

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or “the Company”) (NASDAQ: EIDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • ACCESSWIRE4 months ago

    Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) Investigation

    NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eidos Therapeutics, Inc. ("Eidos" or the "Company") ...

  • ACCESSWIRE4 months ago

    IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 2, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. ("Eidos" or "the Company") (NASDAQ: EIDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • GlobeNewswire4 months ago

    Bragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the Firm

    NEW YORK, April 01, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Eidos Therapeutics, Inc. (NASAQ: EIDX).  Our investigation concerns.

  • Business Wire4 months ago

    INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or “the Company”) (NASDAQ: EIDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Business Wire4 months ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDX

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Eidos Therapeutics, Inc. resulting from allegations that Eidos may have issued materially misleading business information to the investing public.

  • GlobeNewswire4 months ago

    Eidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

    BOSTON, April 01, 2019 -- Block & Leviton LLP (www.blockesq.com), one of the nation’s leading securities litigation firms representing investors nationwide, is.

  • GlobeNewswire4 months ago

    Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions

    AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival in ATTR-CM patients, in all mutant and wild-type subjects. AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM, and is being evaluated in the global Phase 3 ATTRibute-CM study.

  • GlobeNewswire4 months ago

    Eidos Therapeutics to Present at 31st Annual ROTH Conference

    SAN FRANCISCO, March 11, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management is scheduled to participate in a fireside chat regarding Eidos.

  • Can This Biotech Puppy Run With the Big Dogs?
    Motley Fool5 months ago

    Can This Biotech Puppy Run With the Big Dogs?

    Pfizer and Alnylam have a fierce, young contender with a chance to catch up in a big way.

  • GlobeNewswire5 months ago

    Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint

    Eidos Therapeutics, Inc. (Eidos) (EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The design of the ATTRibute-CM study, which incorporates feedback from FDA, includes two potentially registrational endpoints.

  • GlobeNewswire5 months ago

    Eidos Therapeutics to Host Conference Call and Webcast to Discuss ATTR-CM Phase 3 Trial (ATTRibute-CM) Design

    SAN FRANCISCO, Feb. 25, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet.